CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies

  CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within the CAR-T space. Most notably, Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding … Συνεχίστε να διαβάζετε CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies.